EC
PRVL

EcoR1 Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

EcoR1 Capital’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-367,218
Closed -$5.47M – 68
2020
Q2 		$5.47M Sell
367,218
-1,881,088
-84% -$29M 0.41% 33
2020
Q1 		$27.4M Hold
2,248,306
– – 2.86% 15
2019
Q4 		$35.6M Sell
2,248,306
-144,250
-6% -$1.84M 3.38% 11
2019
Q3 		$29.4M Hold
2,392,556
– – 3.92% 11
2019
Q2 		$31.6M Buy
+2,392,556
New +$34.9M 3.25% 12

Other funds holding PRVL

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return